TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05900895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17b-estradiol
Description: 17b-estradiol will be taken orally three times per day.
Study: NCT05624892

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mirror Therapy with Virtual Reality Application
Description: Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
Study: NCT06147544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-718
Description: Administered subcutaneously once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously once a week
Study: NCT05953103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synbixin/Placebo
Description: Synbixin/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synbixin/Placebo
Description: Synbixin/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synbixin/Placebo
Description: Synbixin/Placebo
Study: NCT04999384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 3
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 4
Description: 600mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-food effect
Description: Dose to be determined upon the MTD determination
Study: NCT04683146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis with Propanolol- 1 60%.
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later
Study: NCT04799431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen Vaccine with Poly-ICLC adjuvant
Description: Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: 500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.
Study: NCT05065632

Intervention type: DIAGNOSTIC_TEST
Intervention: Wantai kit Elisa
Description: to mesure antibodies against SARSCov-2 recombinant antigen

Intervention type: DIAGNOSTIC_TEST
Intervention: Wantai kit Elisa
Description: to mesure antibodies against SARSCov-2 recombinant antigen

Intervention type: DIAGNOSTIC_TEST
Intervention: Wantai kit Elisa
Description: to mesure antibodies against SARSCov-2 recombinant antigen

Intervention type: DIAGNOSTIC_TEST
Intervention: Wantai kit Elisa
Description: to mesure antibodies against SARSCov-2 recombinant antigen

Intervention type: DIAGNOSTIC_TEST
Intervention: Wantai kit Elisa
Description: to mesure antibodies against SARSCov-2 recombinant antigen
Study: NCT04605484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Posoleucel (formerly known as ALVR105) cells
Description: Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Posoleucel (formerly known as ALVR105) cells
Description: Infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (visually identical to Posoleucel)
Description: Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (visually identical to Posoleucel)
Description: Infusion
Study: NCT06406283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training (HIFT)
Description: This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The training protocol will be designed based on Cross-Training workouts, emphasizing high-intensity interval training combined with functional resistance-training movements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction Program (MBSR)
Description: This intervention follows the official MBSR program designed by Jon Kabat-Zinn with some adaptations, as we did in Bermudo-Gallaguet, et al. (2022). The intervention will occur three days a week, including one 120-minute online synchronous session and two 20-40 min individual practices. The intensity of physical exercise will be adjusted to personal baseline characteristics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The program includes the Baduanjin sequence, considered one of the most ancient and beneficial forms for physical and mental health within the Qigong tradition.
Study: NCT04983654

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: patients with limb ulcers
Description: For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis ( sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks,~* Analysis of cytokine and metalloproteases in the wound fluid,~* Assessment of healing according usual treatment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: For patients without limb ulcers
Description: For patients without limb ulcers : at inclusion visit only~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis (sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks
Study: NCT06093698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-EpCAM-CD3 Antibody Injection
Description: Intravenous Infusion
Study: NCT04694417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression stocking
Description: Please see the description of the intervention in another section

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium tablet
Description: Please see the description of the intervention in another section

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Please see the description of the intervention in another section
Study: NCT05168527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib,Albumin Paclitaxel,Gemcitabine
Description: The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
Study: NCT06313814

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Swanson ginger capsule
Description: Swanson Ginger Root? gingerols, shogaols, and paradols, and possesses multiple bioactivities, such as antioxidant, anti-inflammatory, and antimicrobial properties.~Ginger is most commonly associated as a culinary spice flavouring to oriental dishes and even the local bakery character biscuit, the gingerbread man. But since ancient times the spice has also been recognized for its health properties, most popular being to settle the stomach, alleviate indigestion and event prevent motion sickness. More recently research has confirmed Ginger's historical effectiveness on digestive health and beyond.
Study: NCT05892471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol injection
Description: Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol injection
Description: Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
Study: NCT06373991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATHENA CAR-T
Description: Phase 1 dose escalation (3+3): dose 1 and dose 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous injection of fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous injection of cyclophosphamide.
Study: NCT05903391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-Printed Finger Splints
Description: The intervention is wearing a novel finger splint produced by a 3D-printer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Finger Splints
Description: This intervention is wearing a finger splint produced by a conventional method using thermoplastic material typically used in a clinical setting
Study: NCT05949463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent teaching unit
Description: The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention group
Description: The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy.
Study: NCT06232473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Please see arm desciption

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Please see arm desciption
Study: NCT05864872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary brachial plexus block
Description: conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary brachial plexus block
Description: conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
Study: NCT06485141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Storage Intervention
Description: Firearm storage information and secure storage device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safe Kids Medication
Description: The Control participants will view a brief medication storage safety video produced by Safe Kids. A Frequently Asked Questions handout on medication safety created by Safe Kids will be available for parents as well.
Study: NCT04683146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis with Propanolol- 1 60%.
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.
Description: * Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later.
Study: NCT06232473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Please see arm desciption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Please see arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Please see arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine Mesylate 0.5 MG and passive placebo RAP
Description: Please see arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benztropine Mesylate 0.5 MG and passive placebo RAP
Description: Please see arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: Please see arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Please see arm description

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced usual care
Description: Please see arm description
Study: NCT05714254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI0618
Description: Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four doses of IV placebo or SC placebo administered once every two weeks.
Study: NCT06355206

Intervention type: COMBINATION_PRODUCT
Intervention: endoscopic intervention, surgery or conservative treatment
Description: Personal information and treatment of the enrolled subjects will be collected.
Study: NCT05707195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit
Study: NCT04752631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: The participants received TNK-tPA thrombolytic therapy
Study: NCT02664740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anti-Staphylococcus bacteriophage therapy
Description: Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
Description: Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
Study: NCT05418140

Intervention type: OTHER
Intervention: Ultrasound diagnosis of adenomyosis
Description: The diagnosis of adenomyosis will be made using transvaginal ultrasound scan (TVS) (2D and 3D Ultrasound and applying Morphological Uterus Sonographic Assessment (MUSA) criteria (Van den Bosch et al, 2015).

Intervention type: OTHER
Intervention: Ultrasound diagnosis of adenomyosis
Description: The diagnosis of adenomyosis will be made using transvaginal ultrasound scan (TVS) (2D and 3D Ultrasound and applying Morphological Uterus Sonographic Assessment (MUSA) criteria (Van den Bosch et al, 2015).
Study: NCT06430736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab before CAR-T cell infusion
Description: Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.~Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab at emerging CRS
Description: Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
Study: NCT05725226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double J Stent 6Fr x 26cms
Description: Surgery will be performed by expert Urologist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double J Stent 4Fr x26cms
Description: Surgery will be performed by expert Urologist.
Study: NCT05880849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline
Description: Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days
Study: NCT05084638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 20mg subcutaneous injection
Study: NCT06237660

Intervention type: PROCEDURE
Intervention: Bronchoscopy, with bronchoalveolar lavage and endobronchial biopsy
Description: These children who will be having a bronchoscopy (a long thin tube, with a camera at the end, which is put inside the lung to look at and collect samples) as part of their standard clinical management, determined by their own consultants or treating physicians. They will be having lung samples (washings from the lung and a tiny piece of tissue taken from the breathing tubes) taken as part of their usual medical management. The research team will ask for consent to use the leftover samples for the bronchoscopy, for the study

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test
Description: To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test
Description: To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test
Description: To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Finger prick blood test
Description: Finger prick testing will be used for blood samples, and it is the same technique used by children with diabetes, to test their blood sugar levels, and therefore is regularly used in this age group successfully. The research team will be obtain the results within minutes, using a point-of-care device. A few more drops of blood, from the same finger prick sample, will be taken to look at how one of the blood cells work, in more detail, in the laboratory. There is no additional finger prick required for this lab test, and the drops of blood will be collected at the same time, from the same prick, as the point of care test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Finger prick blood test
Description: Finger prick testing will be used for blood samples, and it is the same technique used by children with diabetes, to test their blood sugar levels, and therefore is regularly used in this age group successfully. The research team will be obtain the results within minutes, using a point-of-care device. A few more drops of blood, from the same finger prick sample, will be taken to look at how one of the blood cells work, in more detail, in the laboratory. There is no additional finger prick required for this lab test, and the drops of blood will be collected at the same time, from the same prick, as the point of care test.
Study: NCT06243575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal Intraosseous Femoral Injection
Description: Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal Intraosseous Tibial Injection
Description: Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
Study: NCT06114602

Intervention type: BEHAVIORAL
Intervention: E-Mail Reminder
Description: Patients who have an appointment (either face-to-face or teleconsultation) scheduled with a doctor at the Hospital receive an e-mail at the time of their request as well as 14 days and 48 hours prior to the appointment, reminding them of the appointment time and the place where they have to go. In addition, a button has been added to the e-mail so that the patient can click on it and cancel it directly in a simple way.